Neuropathological and imaging findings in IRBD patients—such as reduced dopamine transporter (DAT) binding and aggregated α-synuclein species in CSF—support the assumption that IRBD is indeed an early synucleinopathy [10,11]. This evidence concerns the gene SLC6A3 and synucleinopathy.